09:54 AM EST - BriaCell Therapeutics Corp : Announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer and recommended continuation of the ongoing study without any modifications. BriaCell Therapeutics Corp
shares T.BCT are trading up $0.31 at $6.45.
